top of page

Acute Myeloid Leukemia (AML)

Behaviour

    Aggressive growth
    Widespread involvement
    Variable symptoms: fatigue, weakness, fever, night sweats, loss of appetite.
    Bone pain

Biomarkers

    FLT3 mutation: FLT3-ITD
    Cytogenetics: t(8;21) or inv(16)
    Molecular genetic testing: NPM1, CEBPA, ASXL1
    MRD assessment

Pathology

    Genetic changes
    Cell proliferation
    Bone marrow failure
    Cytopenias

Chronic Lymphocytic Leukemia (CLL)

Behaviour

    Slow progression
    Fatigue
    Weight loss
    Abdominal pain or swelling
    Enlarged spleen or liver

Biomarkers

    TP53 disruption
    NOTCH1 mutation
    MYD88 mutation
    SF3B1 mutation
    ATM mutation

Pathology

    Cell type: CD5+CD23+ B cells
    Genetic abnormalities
    Microenvironment

Non-Hodgkin’s lymphoma

Behaviour

    Fever and chills
    Swollen abdomen
    Chest pain or pressure
    Night sweats
    Shortness of breath or cough
    Unexplained weight loss

Biomarkers

    Serological markers : LDH, β2-MG, CA 125
    Immunophenotypic markers :
    1. CD19, CD20, CD22, CD79, and Pax-5: B-cell markers
    2. CD2, CD3, CD4, CD5, CD7, and CD8: T-cell markers
    3. TIA-1, granzyme B, and perforin: Cytotoxic markers
    4. CD10, Bcl-6, and LMO2: Germinal center markers
    5. CD38 and CD138: Plasma cell markers

Pathology

    Cell origin
    Histological patterns
    Lymph nodes
    Follicular lymphoma
    Diffuse large B-cell lymphoma (DLBCL)

Astrocytoma

Behaviour

    Headaches
    Nausea and vomiting
    Problems speaking
    Feeling very tired or weak
    Poor vision

Biomarkers

    Glial fibrillary acidic protein (GFAP)
    Cell-free DNA (cfDNA)
    IDH mutations
    MicroRNAs (miRNAs)
    Liquid biopsies

Pathology

    Low-grade astrocytomas
    Pilocytic astrocytomas
    IDH mutant astrocytomas

Acute Lymphoblastic Leukemia (ALL)

Behaviour

    Rapid progression
    Fatigue and weakness
    Easy bruising and bleeding
    Swollen lymph nodes
    Bone pain

Biomarkers

    Immunophenotypic markers: CD3, CD19, CD20, CD22, CD24, CD79a
    Chromosomal abnormalities: t(12;21)/ ETV6-RUNX1, t(17;19)/, t(9;22)/
    Other biomarkers: CD34, CD38, TNF-α, Livin

Pathology

    Affects B or T lymphocytes
    Cell development
    Bone marrow
    Blood
    Organs

Multiple Myeloma

Behaviour

    Confusion
    Weakness
    Mood changes
    Fatigue
    Bone pain

Biomarkers

    Monoclonal protein biomarkers
    Imaging biomarkers
    Genetic aberrations
    miRNAs

Pathology

    Bone destruction
    Hypercalcemia
    Paraprotein
    Immunodeficiency
    Anemia
    Bone marrow failure

Glioblastoma (GBM)

Behaviour

    Depression and anxiety
    Social withdrawal
    Loss of inhibitions
    Fatigue
    Muscle weakness or balance issues

Biomarkers

    IDH1/2 mutations
    PD-L1 expression
    TERT promoter mutations
    CD4+ T-cell compartment
    Serum GFAP

Pathology

    Cellular pleomorphism
    Necrosis pattern
    Microvascular proliferation
    Infiltrative growth
    Nuclear atypia

Chronic Myeloid Leukemia (CML)

Behaviour

    Fatigue
    Weight loss
    Night sweats
    Bone pain
    High fever

Biomarkers

    Detection method: BCR-ABL1 fusion gene.
    Clinical significance: TKIs
    Philadelphia chromosome

Pathology

    Philadelphia chromosome
    Tyrosine kinase inhibitors (TKIs)
    Phases: chronic, accelerated, and blast

Hodgkin’s lymphoma

Behaviour

    Fever
    Night sweats
    Unexplained weight loss
    Itchy skin, especially after drinking alcohol
    Fatigue

Biomarkers

    TARC
    CD163
    CD30
    ctDNA
    PET scans

Pathology

    Characteristic cells
    Cellular origin
    Microenvironment
    Nodular Sclerosis
    Mixed Cellularity
    Lymphocyte Depleted

Medulloblastoma

Behaviour

    Fatigue and lack of energy
    Nausea and vomiting
    Hearing loss
    Neck tilt or double vision
    Seizures

Biomarkers

    SPRIGHTLY
    CD271
    SNCA
    CADH1
    FGFR4
    FIBB

Pathology

    WNT pathway: CTNNB1
    Non-WNT/non-SHH
    Cell appearance
    Rosettes
    Medulloblastoma with extensive nodularity (MBEN)
bottom of page